Real-world findings suggest GLP-1 drugs offer health benefits for young people with diabetes

New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from Sept. 28–Oct. 2 examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

≈